SCHEMBL8201126

SCHEMBL8201126

CC/C(=C(\C#N)C(=O)O)C(C)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGS2 P35354 1/20 0.38
LMNA P02545 4/20 0.37
MAPK1 P28482 2/20 0.37
CTSS P25774 2/20 0.36
CTSK P43235 2/20 0.36
CTSL P07711 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 1/20 0.36
XBP1 P17861 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
ALOX5 P09917 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1702752 0.80 PTGS2 (0.42) ALDH1A1TDP1PTGS2LMNAMAPK1
SCHEMBL28647295 0.79 ALDH1A1 (0.43) ALDH1A1TDP1PTGS2LMNAMAPK1
SCHEMBL1245561 0.76 ALDH1A1 (0.44) ALDH1A1TDP1PTGS2LMNAMAPK1
SCHEMBL541122 0.76 FFAR3 (0.31)
SCHEMBL11477347 0.72 PTGS2 (0.47) ALDH1A1PTGS2LMNAMAPK1MAPT
SCHEMBL19357468 0.70 ALDH1A1 (0.47) ALDH1A1PTGS2LMNAMAPK1MAPT
SCHEMBL19357469 0.70 ALDH1A1 (0.47) ALDH1A1PTGS2LMNAMAPK1MAPT
SCHEMBL3410010 0.70 ALDH1A1 (0.50) ALDH1A1PTGS2LMNAMEN1KMT2A
SCHEMBL13389325 0.70 ALDH1A1 (0.50) ALDH1A1PTGS2LMNAMEN1KMT2A
SCHEMBL29119412 0.69 KDM4E (0.43) ALDH1A1TDP1LMNAMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008063668-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 WO disclosed